Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Molecular Detection Inc.

Definitively diagnosing MRSA

This article was originally published in Start Up

Executive Summary

Methicillin-resistant staphylococcus aureus infections are deadly for patients and expensive for hospitals to treat. Current methods of detecting MRSA are plagued with significant numbers of false-positive results. Molecular Detection Inc.’s Detect-Ready screening assay is designed to distinguish accurately if a positive result indicates the presence of MRSA or a combination of different bacteria, some of which may not be resistant to antibiotics. The test can be run with equipment found in most clinical laboratories, enabling hospitals to make informed clinical decisions about the best way to treat patients.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel